Two/CD major/JJ drug/NN companies/NNS posted/VBD strong/JJ third-quarter/NN earnings/NNS ,/, in/IN line/NN with/IN profits/NNS already/RB reported/VBN by/IN industry/NN leaders/NNS and/CC analysts/NNS '/POS expectations/NNS ./.
But/CC Pfizer/NNP Inc./NNP ,/, based/VBN in/IN New/NNP York/NNP ,/, reported/VBD flat/JJ earnings/NNS ./.
Schering-Plough/NNP Corp./NNP ,/, based/VBN in/IN Madison/NNP ,/, N.J./NNP ,/, reported/VBD a/DT #/CD %/NN rise/NN in/IN earnings/NNS as/IN American/NNP Home/NNP Products/NNPS Corp./NNP of/IN New/NNP York/NNP posted/VBD an/DT #/CD %/NN increase/NN in/IN net/NN ./.
American/NNP Home/NNP Products/NNPS
American/NNP Home/NNP Products/NNPS said/VBD sales/NNS and/CC earnings/NNS for/IN the/DT third/JJ quarter/NN and/CC nine/CD months/NNS were/VBD at/IN record/NN levels/NNS ./.
Sales/NNS for/IN the/DT third/JJ quarter/NN increased/VBD #.#/CD %/NN to/TO $/$ #.#/CD billion/CD from/IN $/$ #.#/CD billion/CD ./.
Sales/NNS of/IN health-care/JJ products/NNS increased/VBD #/CD %/NN in/IN the/DT third/JJ quarter/NN ,/, based/VBN in/IN part/NN on/IN strong/JJ sales/NNS of/IN prescription/NN drugs/NNS such/JJ as/IN Premarin/NNP ,/, an/DT estrogen-replacement/NN drug/NN ,/, and/CC sales/NNS of/IN the/DT company/NN 's/POS infant/NN formula/NN ./.
American/NNP Home/NNP Products/NNPS said/VBD net/JJ income/NN benefited/VBD from/IN a/DT ``/`` lower/JJR effective/JJ tax/NN rate/NN ,/, ''/'' reflecting/VBG a/DT reduction/NN of/IN foreign/JJ tax/NN rates/NNS ,/, and/CC additional/JJ operations/NNS in/IN Puerto/NNP Rico/NNP ./.
Net/NN also/RB was/VBD aided/VBN by/IN a/DT gain/NN on/IN the/DT sale/NN of/IN the/DT company/NN 's/POS equity/NN interests/NNS in/IN South/NNP Africa/NNP effective/JJ Sept./NNP #/CD ./.
In/IN New/NNP York/NNP Stock/NNP Exchange/NNP composite/JJ trading/NN yesterday/NN ,/, American/NNP Home/NNP Products/NNPS closed/VBD at/IN $/$ #.#/CD a/DT share/NN ,/, down/IN #/CD cents/NNS ./.
Pfizer/NNP
Pfizer/NNP said/VBD third-quarter/NN sales/NNS increased/VBD #/CD %/NN to/TO $/$ #.#/CD billion/CD from/IN $/$ #.#/CD billion/CD ./.
The/DT company/NN said/VBD net/JJ income/NN was/VBD flat/JJ because/IN of/IN investment/NN in/IN research/NN and/CC development/NN and/CC costs/NNS related/VBN to/TO launches/NNS of/IN several/JJ products/NNS ./.
The/DT company/NN said/VBD the/DT dollar/NN 's/POS continued/VBN strengthening/VBG reduced/VBD world-wide/JJ sales/NNS growth/NN by/IN three/CD percentage/NN points/NNS ./.
Pfizer/NNP posted/VBD its/PRP$ largest/JJS gains/NNS in/IN healthcare/NN sales/NNS ,/, up/IN #/CD %/NN ,/, and/CC consumer/NN products/NNS ,/, up/IN #/CD %/NN ./.
Sales/NNS by/IN the/DT specialty/NN chemicals/NNS and/CC materials/NNS science/NN segments/NNS were/VBD flat/JJ ,/, and/CC sales/NNS by/IN the/DT agriculture/NN segment/NN declined/VBD #/CD %/NN ./.
In/IN the/DT health-care/JJ segment/NN ,/, pharmaceutical/JJ sales/NNS increased/VBD #/CD %/NN and/CC sales/NNS of/IN hospital/NN products/NNS increased/VBD #/CD %/NN ./.
During/IN the/DT quarter/NN ,/, Pfizer/NNP received/VBD federal/JJ approval/NN of/IN Procardia/NNP XL/NNP ,/, a/DT calcium/NN channel/NN blocker/NN approved/VBN for/IN both/DT angina/NN and/CC hypertension/NN ,/, and/CC Monorail/NNP Piccolino/NNP ,/, used/VBN to/TO open/VB obstructed/VBN coronary/JJ arteries/NNS ./.
In/IN New/NNP York/NNP Stock/NNP Exchange/NNP composite/JJ trading/NN yesterday/NN ,/, Pfizer/NNP closed/VBD at/IN $/$ #.#/CD a/DT share/NN ,/, up/IN #/CD cents/NNS ./.
Schering-Plough/NNP
Schering-Plough/NNP said/VBD sales/NNS gained/VBD #.#/CD %/NN to/TO $/$ #.#/CD million/CD from/IN $/$ #.#/CD million/CD ./.
In/IN the/DT period/NN ,/, the/DT company/NN completed/VBD the/DT sale/NN of/IN its/PRP$ European/JJ cosmetics/NNS businesses/NNS ,/, sold/VBD a/DT majority/NN interest/NN in/IN its/PRP$ Brazilian/JJ affiliate/NN ,/, and/CC announced/VBD the/DT reorganization/NN of/IN its/PRP$ over-the-counter/JJ drug/NN businesses/NNS into/IN a/DT new/JJ unit/NN ,/, Schering-Plough/NNP Health/NNP Care/NNP Products/NNPS ./.
These/DT actions/NNS did/VBD n't/RB affect/VB results/NNS because/IN the/DT gain/NN on/IN the/DT sale/NN of/IN the/DT European/JJ cosmetics/NNS businesses/NNS was/VBD offset/VBN by/IN provisions/NNS relating/VBG to/TO the/DT Brazil/NNP divestiture/NN and/CC drug/NN restructuring/NN ./.
U.S./NNP pharmaceutical/JJ sales/NNS rose/VBD #/CD %/NN ,/, led/VBN by/IN allergy/NN ,/, asthma/NN and/CC cold/JJ products/NNS ;/: dermatological/JJ products/NNS ;/: anti-infectives/NNS and/CC anti-cancer/JJ products/NNS ;/: and/CC cardiovascular/JJ products/NNS ./.
World-wide/JJ consumer/NN product/NN sales/NNS declined/VBD #/CD %/NN ,/, primarily/RB because/IN of/IN the/DT European/JJ cosmetics/NNS sale/NN ./.
Significantly/RB lower/JJR sales/NNS of/IN `/`` Stay/NNP Trim/NNP '/'' diet/NN aids/NNS also/RB were/VBD a/DT factor/NN in/IN the/DT drop/NN ./.
The/DT Maybelline/NNP beauty/NN product/NN line/NN had/VBD higher/JJR sales/NNS following/VBG a/DT sluggish/JJ first/JJ half/NN ./.
In/IN Big/NNP Board/NNP composite/JJ trading/NN ,/, Schering-Plough/NNP shares/NNS fell/VBD #/CD cents/NNS to/TO close/VB at/IN $/$ #.#/CD ./.
